Clinical trials: Colon Cancer Stage II
Colorectal Cancer
Study of Fruquintinib in Patients With Metastatic Colorectal Cancer
Fruquintinib administered at 5mg once daily in 4 weeks treatment cycle (three weeks on and one week off) was well tolerated and demonstrated encouraging preliminary clinical antitumor activity in patients with advanced Colorectal…
- Trial name
- NCT02196688
- Testing
- fruquintinib
- Where
- 5 sites in China
- Volunteers
- 71 people
- Sponsor
- Hutchison Medipharma Limited
Adenocarcinoma of the Colon
NEOadjuvant PembRolizumab In Stratified Medicine - ColoRectal Cancer
Colorectal cancer (CRC) is the 2nd to 3rd most common malignant disease in developed countries, with over 1 million new cases and 500,000 deaths worldwide each year.
- Trial name
- NEOPRISM-CRC (NCT05197322)
- Testing
- Pembrolizumab
- Where
- 6 sites in United Kingdom
- Volunteers
- 88 people
- Sponsor
- University College, London
Colon Cancer
A Prospective Study Utilizing Circulating Cell Free DNA (cfDNA) Use in the Detection of RAS Mutations in Patients With Advanced Colorectal Cancer.
Colorectal cancer remains the commonest cancer among men, and third commonest among women in Saudi Arabia . Presentation with metastatic disease occurs in almost one third of patients , with 5-year survival decreasing…
- Trial name
- NCT04775862
- Testing
- investigator choice re-challenge with anti EGFR Rx
- Where
- Saudi Arabia
- Volunteers
- 60 people
- Sponsor
- National Guard Health Affairs
Lynch Syndrome
Preventive Dendritic Cell Vaccination for Lynch Syndrome
The aim of this study is to assess safety, immunogenicity and feasibility of vaccination with neopeptide-loaded dendritic cells in Lynch Syndrome subjects who are known to be carrier of a germline MMR-gene mutation without signs…
- Trial name
- PREVENT-Lynch (NCT07412197)
- Testing
- DC vaccination
- Where
- Netherlands
- Volunteers
- 16 people
- Sponsor
- Radboud University Medical Center
Colonic Neoplasms, Effects of Chemotherapy
A 6 microRNA Tool for Stratifying Stage II Colon Cancer of Receiving Adjuvant Chemotherapy
Whether patients with stage II colon cancer should receive adjuvant chemotherapy or not is still on debate.MicroRNA(miRNA) is a promising tool.
- Trial name
- NCT02466113
- Testing
- A 6 microRNA stratified tool, A classic stratified tool
- Volunteers
- 430 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Stage I Colorectal Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8
Improving Uptake of Surveillance in Colorectal Cancer Survivors Through Navigation and Web Education
This pilot clinical trial looks at whether patient navigation services, an interactive web education intervention, called Current Together After Cancer (CTAC), or both navigation and CTAC works to improve the uptake of…
- Conditions
- Stage I Colorectal Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8
- Trial name
- NCT06995924
- Testing
- Educational Intervention, Electronic Health Record Review, Internet-Based Intervention
- Where
- 2 sites in United States
- Volunteers
- 75 people
- Sponsor
- Fred Hutchinson Cancer Center
Metastatic Colorectal Cancer (CRC)
Fruquintinib Plus Anti-EGFR Antibody for Third-Line Treatment of RAS Wild-Type mCRC
This study aims to evaluate the effectiveness and safety of combining fruquintinib (an oral anti-angiogenesis drug) with cetuximab-beta (an anti-EGFR antibody) in patients with RAS wild-type metastatic colorectal cancer who have…
- Trial name
- NCT07724223
- Testing
- Fruquintinib plus Cetuximab-beta
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Colo-rectal Cancer, Metastatic Cancer
Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer
The investigators propose a phase II clinical trial with the objective to investigate the potential clinical interest to associate regorafenib with a metronomic chemotherapy combining capecitabine, cyclophosphamide and low-dose…
- Trial name
- REPROGRAM-01 (NCT04534218)
- Testing
- Regorafenib, Cyclophosphamide, Capecitabine
- Where
- 3 sites in France
- Volunteers
- 49 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Colorectal Cancer, Liver Metastases
SBRT + PD-1 Monoclonal Antibody in Unresectable Colorectal Liver Metastases
To explore the efficacy and safety of stereotactic body radiation therapy (SBRT) combined with PD-1 monoclonal antibody in the treatment of unresectable colorectal cancer liver metastasis through a prospective study, providing…
- Trial name
- SPARKLE-L (NCT06794086)
- Testing
- Stereotactic body radiation therapy, PD-1 Monoclonal Antibody, Chemotherapy
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Jun Huang
Colorectal Cancer
Effect of G17DT in Patients With Stage II/III Colorectal Cancer
This Phase 2 study was an open label, single-center 18-week study to compare basal and meal stimulated plasma gastrin levels before and after treatment with 3 intramuscular injections of 250 µg G17DT, with and without the…
- Trial name
- CC5 (NCT02518373)
- Testing
- G17DT, Omeprazole
- Volunteers
- 22 people
- Sponsor
- Cancer Advances Inc.
Metastatic Colorectal Cancer
FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI)
The aim of the trial is to optimize response rates and rates of secondary resections of metastases in patients with initially non-resectable metastatic colorectal cancer of RAS wildtype.
- Trial name
- VOLFI (NCT01328171)
- Testing
- FOLFOXIRI + Panitumumab, FOLFOXIRI
- Where
- 19 sites in Germany
- Volunteers
- 93 people
- Sponsor
- AIO-Studien-gGmbH
Colorectal Cancer, RAS Mutation
PD-1 Antibody Plus Bevacizumab and CAPOX as First-line Treatment for RAS-mut MSS mCRC
This study is designed to explore the efficacy and safety of anti-PD-1 antibody plus bevacizumab and chemotherapy as first-line treatment for patients with RAS-mutant, microsatellite stable, metastatic colorectal cancer.
- Conditions
- Colorectal Cancer, RAS Mutation, Colorectal Neoplasms, Microsatellite Stable Colorectal Carcinoma
- Trial name
- NCT06206096
- Testing
- oxaliplatin+capecitabine+bevacizumab+PD-1 antibody
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Chinese PLA General Hospital
Colorectal Neoplasms, Neoplasm Metastasis
Intraoperative Intraportal Chemotherapy Combined With Adjuvant Chemotherapy for Stage II and III Colorectal Cancer
In this study, the investigators assessed whether intraoperative Intraportal infusion of 5-FU and oxaliplatin is able to prevent liver metastasis in patients receiving curative colorectal cancer resection.
- Conditions
- Colorectal Neoplasms, Neoplasm Metastasis, Liver Neoplasms
- Trial name
- NCT01972503
- Testing
- 5-FU and oxaliplatin, colorectal cancer resection+ adjuvant chemotherapy (mFOLFOX6)
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Xu jianmin
Colorectal Cancer, Metastasis
Phase II Study of Simvastatin Plus Irinotecan, Fluorouracil, and Leucovorin(FOLFIRI) for Metastatic CRC
This trial is designed to assess the tolerability and efficacy of simvastatin plus FOLFIRI (irinotecan, 5-FU, leucovorin) in metastatic colorectal cancer patients.
- Trial name
- NCT00313859
- Testing
- simvastatin
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Samsung Medical Center
Recurrent Colorectal Carcinoma, Stage IVA Colorectal Cancer
Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery
This phase I/II trial studies the side effects and best dose of cetuximab when given together with pembrolizumab in treating patients with colorectal cancer that has spread from the primary site (place where it started) to other…
- Conditions
- Recurrent Colorectal Carcinoma, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer
- Trial name
- NCT02713373
- Testing
- Cetuximab, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Roswell Park Cancer Institute
Locally Advanced Rectal Cancer (LARC), Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET)
This study is a prospective, multi-cohort clinical trial designed to evaluate the preliminary efficacy and safety of zanidatamab in combination with tislelizumab and chemotherapy/radiotherapy for patients with HER2-positive…
- Conditions
- Locally Advanced Rectal Cancer (LARC), Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Cancer (mCRC), Neoadjuvant Therapy
- Trial name
- NCT07243938
- Testing
- short-course radiotherapy, Zanidatamab, Tisleizumab(BGB-A317)
- Volunteers
- 70 people
- Sponsor
- Tao Zhang
Colorectal Cancer, Colorectal Carcinoma
Safety Study of the Combination of Panitumumab, Irinotecan and Everolimus in the Treatment of Advanced Colorectal Cancer
This study will assess the safety of panitumumab, irinotecan and everolimus when given in combination to treat advanced colorectal cancer
- Conditions
- Colorectal Cancer, Colorectal Carcinoma, Colorectal Tumors, Neoplasms, Colorectal
- Trial name
- PIE (NCT01139138)
- Testing
- Panitumumab, Irinotecan, Everolimus
- Where
- Australia
- Volunteers
- 49 people
- Sponsor
- The Queen Elizabeth Hospital
Colon Cancer
Herbal Treatment to Improve Chemotherapy Delivery
This study is designed to:(1) determine the efficacy of Traditional Chinese Medicine (TCM) 'Tonifying Spleen and Kidney Sequential Regimen' (TSKSR) in improving the completion rate of 8-cycle CapeOX chemotherapy in patients with…
- Trial name
- HATCHED (NCT03716518)
- Testing
- Tonifying Spleen and Kidney Sequential Regimen
- Where
- 12 sites in China
- Volunteers
- 400 people
- Sponsor
- Xiyuan Hospital of China Academy of Chinese Medical Sciences
Colorectal Cancer Stage II, Colorectal Cancer Stage III
Study of Oral Metronidazole on Postoperative Chemotherapy in Colorectal Cancer
Fusobacterium nucleatum (Fusobacterium nucleatum, Fn) has been identified as an independent risk factor for recurrence of colorectal cancer.
- Trial name
- NCT04264676
- Testing
- Metronidazole Oral Tablet
- Where
- 4 sites in China
- Volunteers
- 294 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Colorectal Neoplasms
Phase II Study of Tislelizumab Combined With Cetuximab and Irinotecan in the Treatment of Recurrent, Refractory mCRC
This is a single arm, open phase II study to evaluate the efficacy and safety of tislelizumab combined with cetuximab + irinotecan in the treatment of Ras wild-type recurrent and refractory colorectal cancer.
- Trial name
- NCT05143099
- Testing
- TEC
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Shanghai Zhongshan Hospital